← Leaderboards
Robert J Devita
Icahn School Of Medicine At Mount Sinai
$8,217,526
Attributed
$19,889,060
Total exposure
10
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.4M · FY2016–25$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,889,060 · 10
By mechanism
R01$18,788,444 · 7
R21$931,532 · 2
R03$169,084 · 1
Top collaborators
- Andrew F. Stewart19 shared
- Adolfo Garcia-Ocana13 shared
- Sander Michel Houten10 shared
- Zhen-Qiang Pan5 shared
- Michael Block Lazarus4 shared
- Inga Peter3 shared
Most similar at Icahn School Of Medicine At Mount Sinai
Same institution · by research overlap
- Sander Michel Houten$3,775,555
- Michael Block Lazarus$6,195,746
Others in their field
Top investigators on “Pharmaceutical Chemistry”
- David Heimbrook · Leidos Biomedical Research, Inc.$143,119,991
- John Damon Chodera · Sloan-Kettering Inst Can Research$49,367,180
- Keith Barnes · Albany Molecular Research, Inc.$41,082,172
- Karen I Goldberg · University Of Washington$37,998,306
- Jay D Keasling · University Of California-Berkeley$37,433,392
- Stephen L Buchwald · Massachusetts Institute Of Technology$31,400,392
Research focus
Pharmaceutical ChemistrySmall MoleculeIn VitroLeadIn VivoPharmaceutical PreparationsBindingFutureBiochemicalPhosphotransferasesNational Institute Of Diabetes And Digestive And Kidney DiseasesAffectStructureAnalogCellsSafetyBaseHigh Throughput ScreeningInhibitorNovel TherapeuticsEnzymesResearch PersonnelFamilyCell Proliferation
Grant awards (37)
Targeting succinyl-CoA:glutarate-CoA transferase as a novel therapeutic strategy for glutaric aciduria type 1$726,266
R01 · FY2025 · HD
Allosteric regulation of lysine degradation as a novel pathophysiological mechanism in glutaric aciduria type 1$725,640
R01 · FY2025 · HD
Allosteric regulation of lysine degradation as a novel pathophysiological mechanism in glutaric aciduria type 1$718,385
R01 · FY2024 · HD
DYRK Inhibitors for Human Beta Cell Expansion$689,139
R01 · FY2024 · DK
Modulate Cullin-RING E3 ubiquitin ligases by small molecule agents$667,632
R01 · FY2024 · CA
Preclinical Validation of Novel Gut-Restricted LRRK2 Inhibitors as Therapeutic Leads for IBD$383,980
R01 · FY2024 · DK
Allosteric regulation of lysine degradation as a novel pathophysiological mechanism in glutaric aciduria type 1$725,595
R01 · FY2023 · HD
DYRK Inhibitors for Human Beta Cell Expansion$717,853
R01 · FY2023 · DK
Modulate Cullin-RING E3 ubiquitin ligases by small molecule agents$688,716
R01 · FY2023 · CA
Biological and Medicinal Chemistry Approaches to Human Beta Cell Regeneration$629,942
R01 · FY2023 · DK
Preclinical Validation of Novel Gut-Restricted LRRK2 Inhibitors as Therapeutic Leads for IBD$399,978
R01 · FY2023 · DK
DYRK Inhibitors for Human Beta Cell Expansion$717,853
R01 · FY2022 · DK
Modulate Cullin-RING E3 ubiquitin ligases by small molecule agents$688,716
R01 · FY2022 · CA
Novel Selective Type II kinase Inhibitors to treat Diabetes$674,446
R01 · FY2022 · DK · contact PI
Biological and Medicinal Chemistry Approaches to Human Beta Cell Regeneration$629,942
R01 · FY2022 · DK
Preclinical Validation of Novel Gut-Restricted LRRK2 Inhibitors as Therapeutic Leads for IBD$399,978
R01 · FY2022 · DK
Substrate reduction as a novel therapeutic strategy for Glutaric Aciduria Type 1$169,000
R21 · FY2022 · HD
A novel treatment option for disorders of propionate metabolism$84,500
R03 · FY2022 · HD
DYRK Inhibitors for Human Beta Cell Expansion$718,915
R01 · FY2021 · DK
Modulate Cullin-RING E3 ubiquitin ligases by small molecule agents$702,771
R01 · FY2021 · CA
Novel Selective Type II kinase Inhibitors to treat Diabetes$674,446
R01 · FY2021 · DK · contact PI
Biological and Medicinal Chemistry Approaches to Human Beta Cell Regeneration$629,942
R01 · FY2021 · DK
Substrate reduction as a novel therapeutic strategy for Glutaric Aciduria Type 1$296,407
R21 · FY2021 · HD
A novel treatment option for disorders of propionate metabolism$84,584
R03 · FY2021 · HD
Modulate Cullin-RING E3 ubiquitin ligases by small molecule agents$702,771
R01 · FY2020 · CA
Novel Selective Type II kinase Inhibitors to treat Diabetes$674,446
R01 · FY2020 · DK · contact PI
Biological and Medicinal Chemistry Approaches to Human Beta Cell Regeneration$629,942
R01 · FY2020 · DK
Novel Selective Type II kinase Inhibitors to treat Diabetes$674,446
R01 · FY2019 · DK · contact PI
Dyrk Inhibitors for Human Beta Cell Expansion$500,283
R01 · FY2019 · DK
Novel Selective Type II kinase Inhibitors to treat Diabetes$419,648
R01 · FY2019 · DK · contact PI
Novel Selective Type II kinase Inhibitors to treat Diabetes$674,446
R01 · FY2018 · DK · contact PI
Dyrk Inhibitors for Human Beta Cell Expansion$500,283
R01 · FY2018 · DK
Novel Treatment Options for Glutaric Aciduria$169,500
R21 · FY2018 · HD
Dyrk Inhibitors for Human Beta Cell Expansion$561,169
R01 · FY2017 · DK
Novel Treatment Options for Glutaric Aciduria$296,625
R21 · FY2017 · HD
Dyrk Inhibitors for Human Beta Cell Expansion$500,283
R01 · FY2016 · DK
Dyrk Inhibitors for Human Beta Cell Expansion$40,592
R01 · FY2016 · DK